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Effect of phenoxybenzamine on cardiovascular and plasma 
catecholamine responses to clonidine 
To determine whether the alpha-adrenergic antagonist phenoxybenzamine would alter 
cardiovascular or plasma catecholamine response to the alpha-adrenergic agonist clonidine, six 
patients with pheochromocytomas and eight with labile hypertension were studied. Clonidine, 
0.3 mg, was given with and without 48 hr pretreatment with 30 mg /day phenoxybenzamine. The 
response to 10 mg diazepam was also observed in seven of the subjects who had labile 
hypertension. In the hypertensive patients, clonidine alone induced a fall in supine blood 
pressure from 137 ± 21191 ± 14 to 109 ± 18176 ± 17 mm Hg and, with phenoxybenzamine, 
clonidine reduced blood pressure from 141 ± 22189 ± 10 to 107 ± 21172 ± 11 mm Hg. 
Plasma norepinephrine fell from 179 ± 60 to 107 ± 79 pg 1ml without phenoxybenzamine and 
from 229 ± 159 to 95 ± 46 pglml with phenoxybenzamine in hypertensive subjects. Responses 
with phenoxybenzamine did not differ from those without phenoxybenzamine and diazepam 
induced no cardiovascular or plasma catecholamine changes. Clonidine did not lower plasma 
catecholamines in patients with a pheochromocytoma in the presence or in the absence of 
phenoxybenzamine. Blood pressure tended to decline after clonidine in pheochromocytoma 
patients not taking phenoxybenzamine, but it was not reduced by clonidine when these patients 
were taking phenoxybenzamine. Phenoxybenzamine does not inhibit reduction in blood pressure 
and plasma catecholamines induced by clonidine in patients with essential hypertension or 
interfere with the clonidine suppression test in patients with pheochromocytomas. 
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Clonidine is an imidazoline derivative that is 
widely used as an antihypertensive drug. It 
lowers blood pressure and heart rate by stim- 
ulating postsynaptic alpha-adrenergic receptors 
Supported in part by grants from the National Institutes of Health 
to the Clinical Research Center, University of Michigan Medical 
School (5-M0I-RR-42) and the Division of Hypertension (HL 
21893), and the Nuclear Medicine Research Fund. 
Received for publication May 17, 1982. 
Accepted for publication Sept. 13, 1982. 
Reprint requests to: Andrew J. Zweifler, M.D., Division of Hy- 
pertension, Box 48, R6669 Kresge Medical Research Building, 
University of Michigan Medical Center, Ann Arbor, MI 48109. 
in the central nervous system.9' 15 Clonidine also 
decreases plasma norepinephrine after short- and 
long-term administration; an absence of this re- 
sponse has been reported recently to be diag- 
nostic of a pheochromocytoma .1 Despite the 
fact that, in animals, the hypotensive action of 
clonidine is blocked by a range of alpha-antag- 
onists,8' 18 there has been little systematic in- 
vestigation of the effect of alpha-blockers on the 
action of clonidine in man. Infusion of phentol- 
amine has been reported to increase plasma nor- 
epinephrine concentration in normal subjects 
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Table I. Recumbent plasma catecholamines 
and blood pressure in patients 
*Taking phenoxybenzamine, 20 mg/day. 
taking clonidine,'2 but there has been no study 
of the effect of phenoxybenzamine on any of the 
responses to clonidine in man. We have re- 
corded blood pressure, heart rate, and plasma 
catecholamine changes induced by clonidine 
with and without phenoxybenzamine pretreat- 
ment in 14 patients (six with pheochromocy- 
tomas and eight with labile hypertension). We 
also observed the response to diazepam in seven 
patients in the latter category. 
Materials and methods 
Subjects. Our subjects were eight patients 
with labile hypertension suspected of having a 
pheochromocytoma, but found to have normal 
rates of urinary catecholamine excretion and 
normal plasma catecholamine concentrations, 
and six with pheochromocytomas that were ul- 
timately removed surgically. The eight who 
proved not to have a catecholamine-secreting 
tumor were selected for study because of a his- 
tory of intermittent or unusually variable hy- 
pertension and associated symptoms such as 
headache, flushing, sweating, and palpitations. 
Baseline blood pressure and plasma catechol- 
amine levels are recorded in Table I. 
Clonidine response. Patients were admitted 
to the Clinical Research Center and studied in 
the fasted state and after at least 30 min of re- 
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Fig. 1. Change in diastolic blood pressure in eight 
hypertensive patients and mean change for the group (..) after clonidine (0.3 mg orally) with (panel B) 
and without (panel A) phenoxybenzamine pretreat- 
ment. *P < 0.05; **P < 0.01 vs. time 0. 
cumbency. Cigarettes, coffee, and tea were not 
permitted for 24 hr before the experiments. A 
19-gauge butterfly needle was introduced into a 
peripheral vein at 7:30 A.M. and patency of the 
line was maintained with heparinized saline (15 
units/m1). Blood samples were not drawn until 
at least 30 min after the placement of the venous 
line. A 0.3-mg dose of clonidine was given 
orally and blood samples were obtained at 5, 
60, 120, 150, and 180 min. This dose was se- 
lected after pilot experiments with 0.5 mg (the 
dose used by Metz et al.'2) resulted in rather 
marked somnolence and hypotension in normal 
subjects. Hossmann et al.5 had also demon- 
strated that 0.3 mg clonidine induces substantial 
cardiovascular and sedative effects. The blood 
samples were placed into prechilled tubes con- 
taining EDTA and glutathione; the tubes were 
centrifuged promptly and the plasma was then 
decanted and frozen. Recumbent auscultatory 
blood pressure and heart rate measurements 
Norepi- 
nephrine Epinephrine BP 
Diagnosis (pglml) (pg Iml) (mm Hg) 
Hypertensive 119 21 150/110 
208 20 154/98 
152 26 114/80 
105 34 150/85 
176 22 135/100 
247 58 150/90 
247 57 96/64 
230 47 144/100 
Pheochromo- 1347 28 140/90 
cytoma 589* 324* 104/66* 
7188 1427 160/90 
1097 54 138/90 
2339 96 153/108 
2251 152/90 
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Table II. Maximum decrement (±SEM) in plasma norepinephrine, blood pressure, and 
heart rate during a 3-hr period after short-term clonidine (0.3 mg) and after diazepam (10 mg) 
*P < 0.05; tP < 0.01 vs. time 0. 
were obtained at 0, 60, 120, 150, and 180 min 
by a nurse or one of the investigators. 
Clonidine and diazepam. To determine the 
significance and specificity of the hemodynamic 
and plasma catecholamine changes after cloni- 
dine, seven of the patients with labile hyperten- 
sion were also studied after oral diazepam (10 
mg). Diazepam was chosen rather than an inert 
placebo in an effort to approximate the hypnotic 
effect of clonidine. Blood pressure and heart 
rate were measured at 0, 60, 120, 150, and 180 
min in six patients and sequential blood samples 
for plasma norepinephrine determination were 
obtained in seven patients. The effect of diaze- 
pam was determined 24 hr after the effect of 
clonidine had been measured. 
Effect of phenoxybenzamine on the cloni- 
dine response. The clonidine response was ob- 
served twice, before and after phenoxybenza- 
mine, in all eight of the patients with labile 
hypertension and two patients with pheochro- 
mocytomas. Three patients with pheochromocy- 
tomas were studied without phenoxybenzamine 
and one was studied twice while taking phen- 
oxybenzamine over a long term. Phenoxyben- 
zamine was given twice a day in a total daily dose 
of 30 mg for 48 hr before the clonidine test and 
10 mg phenoxybenzamine was given the morn- 
ing of the test. 
Plasma norepinephrine and epinephrine were 
determined by radioenzymatic assay." Stu- 
dent's paired was used for within-group analy- 
sis and the unpaired test was used for compari- 
son of groups. 
Results 
Clonidine versus diazepam. Patients be- 
came drowsy within an hour of receiving either 
medication and usually slept lightly through the 
remainder of the experiment. Substantial and 
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significant reductions in blood pressure and 
heart rate were noted after clonidine, but not 
after diazepam (Table II). Plasma norepineph- 
rine concentrations also declined more after 
clonidine, but this change was not significant. 
Effect of phenoxybenzamine on the 
clonidine response 
Blood pressure and heart rate 
LABILE HYPERTENSION. Blood pressure fell 
below control levels 1 hr after clonidine and had 
not recovered at 3 hr (Table III). Baseline blood 
pressure and the hypotensive response to clon- 
idine was no different after phenoxybenzamine 
(Table III; Fig. 1), although the percent fall in 
pressure tended to be somewhat greater (Fig. 
2). Heart rate was below baseline 2 and 3 hr 
after clonidine. If anything, this effect was in- 
tensified by phenoxybenzamine (Fig. 3). 
PHEOCHROMOCYTOMA. Although blood pres- 
sure tended to decline after clonidine, this effect 
was significant at only one observation point 
(Table III). There were no significant heart rate 
changes. After phenoxybenzamine the baseline 
blood pressure was not significantly lower and 
clonidine did not alter blood pressure or heart 
rate. 
Plasma catecholamines 
LABILE HYPERTENSION. Plasma norepineph- 
rine declined progressively after clonidine, but 
the response became a significant one only 3 hr 
after the drug was taken (Table IV). Plasma 
norepinephrine appeared to fall more rapidly 
after phenoxybenzamine, but percent reduction 
of norepinephrine was similar on both occasions 
(Fig. 4). Clonidine had no effect on plasma epi- 
nephrine concentration with or without phen- 
oxybenzamine. 
PHEOCHROMOCYTOMA. Plasma catechol- 
amine concentrations appeared to increase after 
clonidine, but not significantly so. Clonidine 
Parameter Clonidine Diazepam 
Systolic blood pressure (mm Hg) 6 38.7 ± 21.2t 5.7 ± 8.6 
Diastolic blood pressure (mm Hg) 6 21.2 ± 16.8* 0.3 -± 8.3 
Heart rate (bpm) 6 12.3 ± 8.4* 3.7 ± 6.3 
Plasma norepinephrine 7 35.6 ± 62.4 7.7 ± 43.2 
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Fig. 2. Percent reduction in systolic blood pressure 
(-± SEM) in eight hypertensive patients given 0.3 mg 
clonidine with and without phenoxybenzamine pre- 
treatment. 
during phenoxybenzamine therapy had similar 
effects (Table IV). 
Discussion 
Our data demonstrate that phenoxybenza- 
mine does not inhibit the decrease in blood 
pressure, heart rate, and plasma norepinephrine 
concentration induced by clonidine. There is, in 
fact, a suggestion that phenoxybenzamine 
potentiates these effects. This finding is in ap- 
parent conflict with the results of Metz et al.,' 
who reported that infusion of the alpha-adren- 
ergicreceptor blocker phentolamine reversed 
the reduction of plasma norepinephrine in nor- 
mal subjects receiving clonidine. The two stud- 
ies were designed quite differently, however, 
and the subjects are dissimilar. This may ex- 
plain the discrepancy, but a review of the phar- 
macology of clonidine, phenoxybenzamine, and 
phentolamine allows another explanation. Clon- 
idine is an alpha-adrenergic agonist that has a 
special affinity for alpharreceptors, but also 
occupies alpha,-receptors. It enters the brain 
readily and lowers blood pressure primarily by 
inhibiting sympathetic outflow from the central 
nervous system9; however, a peripheral action 
may also be important, particularly in relation 
to its effect on heart rate." 
Phentolamine is an alpha-adrenergic antag- 
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Fig. 3. Change in heart rate in eight hypertensive 
patients and mean change for the group (s .) after 
clonidine (0.3 mg orally) with (panel B) and without 
(panel A) phenoxybenzamine pretreatment. *13 < 
0.05 and **P < 0.01 vs. time 0. 
onist that blocks alpharreceptors only slightly 
more than alpha2-receptors2 and it does not have 
notable central nervous system effects." Phen- 
oxybenzamine, on the other hand, is an alpha- 
adrenergic antagonist that has quantitatively dif- 
ferent effects on alpha,- and alpha,-receptors. 
In the perfused cat spleen, Dubocovich and 
Langer3 observed phenoxybenzamine to be 30 
times as potent in blocking alpha, than alpha, 
responses during nerve stimulation. Moreover, 
epinephrine-induced aggregation of human 
blood platelets, which is almost certainly sub- 
served by an alpharreceptor, is blocked by 
phentolamine and not by phenoxybenzamine.6 
Phenoxybenzamine enters the central nervous 
system," but has not been observed to inhibit 
the central nervous system effects of clonidine 
in animals .7' 16 
2 3 
Panel B 
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Table III. Effect of clonidine on blood pressure and heart rate in patients taking and 
not taking phenoxybenzamine 
SBP = systolic blood pressure in mm Hg (-±SD); DBP = diastolic blood pressure in mm Hg (-±SD); HR = heart rate in bpm (-±SD). 
*13 < 0.05; tP < 0.01 vs. time 0. 
Table IV. Effect of clonidine on plasma catecholamines in patients taking and 
not taking phenoxybenzamine pretreatment 
Phenoxybenzamine would therefore not be 
expected to inhibit the response to clonidine in 
man, since clonidine's cardiovascular and hor- 
monal effects are due to stimulation of alpha2- 
receptors that phenoxybenzamine does not an- 
tagonize or can only block when present in high 
concentration. A recent investigation in patients 
with essential hypertension demonstrated that 
phenoxybenzamine in the dose range used in 
our study did not increase plasma norepineph- 
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rine concentration in recumbency, although it 
did reduce upright blood pressure." Blockade 
of alpha2-receptors should elevate plasma nor- 
epinephrine concentration. Apparently the dose 
of phenoxybenzamine that is clinically accept- 
able antagonizes alpharreceptors but has no 
substantial effect on alpha2-receptors and there- 
fore is not capable of blocking the action of 
clonidine. 
The situation is not so clear in the case of 
Hours after clonidine 
0 2 2.5 3 
NE NE NE NE NE 
Hypertensives (n -= 8) 
Clonidine 179 38 151 41 141 44 124 33 107* 39 
(60) (16) (55) (17) (86) (26) (85) (13) (79) (33) 
Clonidine and phen-229 52 182 45 112* 37 124 34 95* 31 
oxybenzamine (159) (27) (146) (32) (51) (20) (74) (27) (46) (13) 
Pheochromocytoma 
Clonidine (n = 5) 2844 401 4102 326 3843 315 5728 248 2172 249 
(2489) (684) (2871) (556) (2231) (527) (5338) (365) (1115) (348) 
Clonidine and phen-1610 246 2484 191 2720 281 3332 199 2886 228 
oxybenzamine (1297) (194) (3439) (128) (4340) (215) (3820) (107) (4301) (150) 
(n = 3) 
Hours after clonidine 
0 2 
SBP DBP HR SBP DBP HR SBP DBP HR 
Hypertensive (n -= 8) 
Clonidine 137 91 78 127 81* 71 115t 75f 70* 
(21) (14) (15) (22) (10) (13) (20) (12) (12) 
Clonidine and phenoxybenzamine 141 89 85 115 75t 73* 106 71f 69t 
(22) (10) (7) (18) (11) (9) (19) (10) (10) 
Pheochromocytoma 
Clonidine (n = 5) 149 94 80 134 88 76 134 84t 76 
(9) (8) (13) (16) (12) (14) (23) (11) (15) 
Clonidine and phenoxybenzamine 115 74 73 111 78 74 110 79 74 
(n = 3) (17) (8) (5) (7) (14) (3) (11) (15) (4) 
NE = plasma norepinephrine in pg/ml (-±SD); E = plasma epinephrine n pg/ml (-±SD). 
*P <0.05 vs. time 0. 
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phentolamine since, although more balanced 
than phenoxybenzamine in its antagonism of al- 
pha,- and alpha2-receptors, it is relatively less 
effective in penetrating the central nervous sys- 
tem. Perhaps phentolamine blocks only the pe- 
ripheral action of clonidine, particularly when 
administered over a short term. This might ex- 
plain the failure of blood pressure to rise while 
plasma norepinephrine increased to control lev- 
els when Metz et al.12 infused phentolamine 
into clonidine-treated normal subjects. 
Our major finding is that clonidine may be gi- 
ven to patients taking phenoxybenzamine with- 
out loss of clonidine's effects. This may have 
both diagnostic and therapeutic implications. 
The clonidine suppression test has been recently 
reported to be of value in the diagnosis of pheo- 
chromocytoma in patients with moderate eleva- 
tions of plasma norepinephrine concentration) 
Plasma catecholamines are not lowered by clon- 
idine in patients with sporadic pheochromocy- 
toma. We have, in fact, observed a tendency for 
plasma catecholamines to rise in response to 
clonidine in patients with pheochromocytomas. 
This may be a reaction to blood pressure de- 
cline, which is modest, but it may also result 
from blockade of alpha2-receptors by clonidine, 
which is known to act as an alpha2-antagonist in 
the presence of high concentrations of catechol- 
amines.17 Our data reveal that pretreatment with 
phenoxybenzamine does not alter the pattern 
of change in plasma norepinephrine concentra- 
tion after clonidine dosing in patients with 
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Fig. 4. Percent reduction in plasma norepinephrine 
concentration (± SEM) in eight hypertensive patients 
given 0.3 mg clonidine with and without phenoxy- 
benzamine pretreatment. 
pheochromocytomas. Patients suspected of hav- 
ing such tumors and being treated with phen- 
oxybenzamine need not have the drug discon- 
tinued to undergo the clonidine suppression 
test. 
The possibility that the combination of 
clonidine and phenoxybenzamine might be use- 
ful in the treatment of hypertension is of thera- 
peutic interest. Occasionally there is a rapid and 
potentially dangerous rise in blood pressure after 
discontinuation of clonidine4 that relates to its 
rather short duration of action. Phenoxybenza- 
mine, on the other hand, has a prolonged effect. 
In cases in which clonidine, along with other 
antihypertensive medication, might be stopped 
abruptly by accident or by design, the presence 
of phenoxybenzamine in the therapeutic regimen 
might be of value, since, long after discontinu- 
ation, its residual alpharblocking action might 
protect against "clonidine rebound." 
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